Life Sciences Partner Discusses Upcoming FDA Changes Under Trump Administration
Life sciences partner Albert Cacozza (Washington, D.C.) was quoted in a Jan. 3 Dickinson’s FDA Webview article on a Ropes & Gray podcast about coming changes to the U.S. Food and Drug Administration (FDA) under the Trump administration.
Mr. Cacozza notes that President-elect Trump is a “big wild-card” in the public policy debate over drug pricing. “On the campaign trail, he railed against high drug prices, and vowed to use his negotiating skills to drive them down. Since the election, he has publicly chastised several large companies, so far in the defense sector, over high costs for certain government contracts. So it is possible he may use the bully pulpit to criticize certain high drug prices, and he will have support from a bipartisan group of legislators.
Mr. Cacozza identifies three key issues of particular interest to drug and medical device manufacturers: changes at the FDA with the Trump administration, implementation of the 21st Century Cures Act and reauthorization of the drug user fee act.